Supplementary Table 3. GMT and seroconversion rate comparisons for QIV versus TIV in subjects 6 months to < 9 years of age who received within-specification lots of vaccine.

			QIV	Comparator vaccine			
Endpoint	**Comparison**	**Strain**	**Value (95% CI)**	**Vaccine**	**Value (95% CI)**	**GMT ratio or seroconversion rate difference**	**Comparison criteria met?**
GMT						**---GMT ratio---**	
	Non-inferiority[a]	A/H1N1	1124 (1060; 1192)	Pooled TIV[b]	1160 (1048; 1284)	0.97 (0.86; 1.09)	Yes
		A/H3N2	822 (783; 862)	Pooled TIV	797 (733; 867)	1.03 (0.94; 1.13)	Yes
		B/Brisbane	86.1 (81.8; 90.6)	Licensed TIV	63.9 (57.9; 70.5)	1.35 (1.20; 1.51)	Yes
		B/Florida	61.5 (58.6; 64.7)	Investigational TIV	59.7 (49.5; 72.1)	1.03 (0.86; 1.23)	Yes
	Superiority[c]	B/Brisbane	86.1 (81.8; 90.6)	Investigational TIV[d]	20.7 (17.0; 25.2)	4.16 (3.47; 4.98)	Yes

	B/Florida	61.5 (58.6; 64.7)	Licensed TIV[d]	16.4 (14.9; 18.0)	3.76 (3.36; 4.20)	Yes
Seroconversion rate (%)					**--- Difference in rate ---**	
Non-inferiority[e]	A/H1N1	92.4 (91.2; 93.4)	Pooled TIV	91.6 (89.4; 93.4)	0.77 (−1.32; 3.15)	Yes
	A/H3N2	88.0 (86.6; 89.3)	Pooled TIV	82.9 (80.1; 85.5)	5.13 (2.30; 8.20)	Yes
	B/Brisbane	71.8 (69.9; 73.6)	Licensed TIV	60.7 (56.6; 64.7)	11.09 (6.77; 15.52)	Yes
	B/Florida	66.1 (64.1; 68.0)	Investigational TIV	64.5 (57.6; 70.9)	1.63 (−4.82; 8.55)	Yes
Superiority[f]	B/Brisbane	71.8 (69.9; 73.6)	Investigational[d] TIV	20.4 (15.2; 26.5)	51.41 (45.18; 56.61)	Yes
	B/Florida	66.1 (64.1; 68.0)	Licensed TIV[d]	18.1 (15.0; 21.5)	47.99 (44.12; 51.48)	Yes

Immunogenicity analyses were performed on the per-protocol analysis set: QIV, N = 2339; pooled TIV, N=1181; licensed TIV, N=582; investigational TIV, N=599. The numbers of subjects who received in-specification lots of vaccine and had a valid serology result were 2329−2338 for QIV, 783−786 for pooled TIV, 575 for licensed TIV, and 211 for investigational TIV. Abbreviations: CI, confidence interval; GMT, geometric mean titer; QIV, quadrivalent influenza vaccine; TIV, trivalent influenza vaccine.

[a] Non-inferiority for GMT was met if the lower limit of the 2-sided 95% CI of the GMT_{QIV}/GMT_{TIV} ratio was > 0.66.

[b] The pooled TIV group includes subjects vaccinated with either licensed TIV or investigational TIV, combined.

[c] Superiority for GMT was met if the lower limit of the 2-sided 95% CI of the GMT_{QIV}/GMT_{TIV} ratio was > 1.5.

[d] Investigational TIV did not contain B/Brisbane; licensed TIV did not contain B/Florida.

[e] Non-inferiority for seroconversion rate (SCR) was met if the lower limit of the 2-sided 95% CI of the SCR_{QIV} minus SCR_{TIV} difference was > −10%.

[f] Superiority for SCR was met if the lower limit of the 2-sided 95% CI of the SCR_{QIV} minus SCR_{TIV} difference was > 10%.